Irizarry AR, Yan G, Zeng Q, et al. Defective enamel and bone development in sodium-dependent citrate transporter (NaCT) Slc13a5 deficient mice. PLoS One. 2017;2(4):e0175465.
Lobera M, Madauss KP, Pohlhaus DT, et al. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013;9(5):319-325.
Rong JX, Klein JL, Qiu Y, et al. Rosiglitazone induces mitochondrial biogenesis in differentiated murine 3T3-L1 and C3H/10T1/2 adipocytes. PPAR Res. 2011;2011:179454.
James Rong, Ph.D.
James Rong is a senior group leader intranslational sciences in the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard. Within the program, his research is focused on drug discovery for cancer, trying to address unmet medical needs to patients.
Rong joined the Broad Institute in 2018 after a six-year tenure with Eli Lilly & Co.’s China R&D Center in Shanghai, where he served as Associate Research Director and subsequently Research Director in a newly established research center for metabolic diseases and complications in China, engaged in multiple exploratory drug discovery projects on diabetes, obesity and non-alcoholic steatohepatitis. He has further prior experience as a senior investigator/manager for GlaxoSmithKline, in charge of phenotypic screening, target identification and validation for drug discovery programs.
James obtained his Ph.D. in pathobiology at the University of Southern California and undertook postdoctoral research at Mount Sinai School of Medicine. He also holds a B.S. in chemistry from Peking University.
Contact James Rong via email at email@example.com.